Health / Novo Nordisk Novo Nordisk's New Obesity Drug Fails a Big Test CagriSema does not outperform Zepbound in trial, and Novo's stock sinks By John Johnson withNewser.AI Posted Feb 23, 2026 5:51 AM CST Copied Back